ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discuss need for educational resources and the use of Vivitrol for public health
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Medicare/Medicaid MMM
Maintain the program's six protected classes with respect to depression and schizophrenia
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Pharmacy PHA
DEA regulatory transparency in controlled substances scheduling person DEA regulatory transparency in issuing research licenses and quotas
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Advance the use of FDA-approved medicines to treat addiction in criminal justice settings H.R.3465/S.1690, The Second Chance Act of 2013 - use of FDA approved medicines in criminal justice settings S.1675, Recidivism Reduction and Public Safety Act of 2013 - us of FDA approved medicines in criminal justice settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.